Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ras processing as a therapeutic target in hematologic malignancies.

Doan Thuy Le1, Kevin M Shannon

  • 1Department of Pediatrics and Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California 94143-0519, USA.

Current Opinion in Hematology
|June 4, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Demonstration of Coronary Sinus Reentry by Ultrahigh-Resolution Mapping in Adults With Congenital Heart Disease.

Circulation. Arrhythmia and electrophysiology·2025
Same author

Genomic landscape and clonal architecture in pediatric myeloid neoplasms with chromosome 7 deletions.

Blood neoplasia·2025
Same author

Age-Related Ventricular Tachycardia Substrate Characteristics for Repaired Tetralogy of Fallot Before Transcatheter Pulmonary Valve Placement.

JACC. Clinical electrophysiology·2025
Same author

Multidetector Computed Tomography Assessment of Anatomical Ventricular Tachycardia Isthmuses in Repaired Tetralogy of Fallot.

JACC. Clinical electrophysiology·2024
Same author

Sinus rhythm QRS morphology reflects right ventricular activation and anatomical ventricular tachycardia isthmus conduction in repaired tetralogy of Fallot.

Heart rhythm·2023
Same author

Conduction System Pacing Versus Conventional Cardiac Resynchronization Therapy in Congenital Heart Disease.

JACC. Clinical electrophysiology·2023

Inhibiting farnesyltransferase, which processes oncogenic Ras, is a promising cancer therapy. This review covers farnesyltransferase inhibitors and their efficacy in myeloid malignancies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Signal transduction pathways are crucial in cancer development.
  • Hyperactive Ras signaling drives many hematologic malignancies.
  • Posttranslational processing of Ras by farnesyltransferase is essential for its oncogenic activity.

Purpose of the Study:

  • To review the biological insights into farnesyltransferase.
  • To discuss the development of farnesyltransferase inhibitors.
  • To summarize preclinical and clinical data on these inhibitors in myeloid malignancies.

Main Methods:

  • Review of laboratory studies on farnesyltransferase.
  • Analysis of preclinical and clinical trial data.
  • Discussion of alternative strategies targeting Ras.

Related Experiment Videos

Main Results:

  • Farnesyltransferase inhibition is a rational therapeutic strategy for Ras-driven cancers.
  • Specific inhibitors are under evaluation as cancer therapeutics.
  • Preclinical and clinical data in myeloid malignancies are summarized.

Conclusions:

  • Farnesyltransferase inhibitors represent a promising therapeutic avenue for hematologic malignancies.
  • Targeting Ras posttranslational processing offers a viable strategy.
  • Further research into Ras-targeting therapies is warranted.